Skip to Main Content

Paper Details

Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
JAMA Intern Med
17
2022
Chronic Heart Failure, Empagliflozin, HFpEF, Heart Failure, Patients, cardiovascular, diabetes, empagliflozin, heart failure, patient, patients
Author NameAffiliation
John A SpertusSt Luke's Mid America Heart Institute, University of Missouri-Kansas City.
John A SpertusSt Luke's Mid America Heart Institute, University of Missouri-Kansas City.
Paul A HeidenreichStanford University
Paul A Heidenreich
Alexander T SandhuStanford University
  • 1 - 5

Datasets

Release 1.2